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Azobenzene photoresponsive elements can be installed on 
sulfonylureas, yielding optical control over pancreatic beta 
cell function and insulin release. An obstacle to such 
photopharmacological approaches remains the use of 
ultraviolet-blue illumination. Herein, we synthesize and test a 
novel yellow light-activated sulfonylurea based on a 
heterocyclic azobenzene bearing a push-pull system.  
Type 2 diabetes (T2D) is a modern pandemic currently affecting ~ 
6% of the global population. This disease is characterized by 
diminished insulin secretion from pancreatic beta cells, which 
together with peripheral resistance to the secreted hormone, leads to 
defective glucose homeostasis.1 The resulting elevated glucose 
concentration drives a variety of complications including heart 
disease, cancer, retinal degeneration, and nerve and vascular 
problems.2 
While current medical treatments work well, they are 
associated with complications largely due to off-target or persistent 
actions.3 Moreover, they are unable to recreate pulsatile insulin 
release, a more effective signal for glucoregulation.4 Thus, T2D is 
ideally suited to photopharmacology, which harnesses the temporal 
precision of light to spatiotemporally deliver drug activity.5 We have 
recently shown that a sulfonylurea possessing an azobenzene 
photoresponsive element (a.k.a. AzoSulfonylurea) can be used to 
optically control beta cell function and insulin release via its effects 
on ATP-sensitive potassium (KATP) channels and Exchange Protein 
directly Activated by cAMP 2A (Epac2A) signalling.6 
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However, a significant barrier to the use of such ‘azo-drugs’ for T2D 
treatment is their ultraviolet-blue absorption spectra, increasing 
phototoxicity and limiting tissue penetration due to photon 
scattering.7 By contrast, visible/near infrared wavelengths 
demonstrate better penetrance in the body. 8 
Spurred on by recent studies of ortho- or para-substituted 
azobenzenes,9-11 we therefore devised a novel approach for the 
synthesis of wavelength-tuned photopharmaceuticals with red-
shifted photochromism. An AzoSulfonylurea based on glimepiride 
was achieved by installing a heterocyclic aromatic unit, rather than 
sterically bulky electron-donating halogen or amine moieties 
(Scheme 1).  
 
Scheme 1 (a) Structures of glimepiride (Glim) and the original blue light-
responsive AzoSulfonylurea JB253 for comparison. (b) The logic of a red-
shifted AzoSulfonylurea. Following illumination with green-yellow light (1), 
the AzoSulfonylurea binds Epac2A, closing KATP channels (2) and opening 
voltage-dependent Ca2+ channels (Cav) (3). This allows optical control of 
Ca2+ influx (4) and insulin secretion (5). (c) Synthesis of the AzoSulfonylurea 
JB558 that can be switched from the trans- to the cis-isomer using 
green/yellow light.  
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Starting with the deacetylation of acetazolamide (1) in refluxing 
HCl, heterocycle 2 was obtained that could be further diazotized 
with in situ generated HNO2. Trapping the resulting diazonium salt 
with N, N-diethylaniline generated sulfonamide azobenzene 3. 
Finally, reaction with cyclohexyl isocyanate yielded JB558 via 
acylation of the sulfonamide, giving unprecedented access to a 
sulfonylurea containing a heterocyclic azobenzene. While yields 
were reduced compared to the previously described JB253 (37% 
versus 97%),6 this was most likely due to the presence of a less 
reactive sulfonamide intermediate, as predicted by the lower pKa 
value for 3 (7.36, Fig. S1) and JB558 (2.35, see SI). 
 
 
Fig 1 (a) UV-Vis spectra of JB558 in DMSO following illumination with  = 
520 nm (green) or under dark-adapted conditions (black). (b) Robust 
photoswitching between cis- and trans-JB558 induced with  = 520 nm and 
dark, respectively. 
 
JB558 possessed a red-shifted absorption spectra (max = 
526 nm) in DMSO (Fig. 1a), and could be repeatedly photoconverted 
to its cis-state with green-yellow light ( = 520 nm) (Fig. 1b). 
Thermal back relaxation occurred rapidly in the dark and switching 
kinetics were within the millisecond range (cis = 64.9 ± 1.5 ms; 
trans = 410.8 ± 12.6 ms), without obvious decomposition (Fig. 1b). 
JB558 was stable in the presence of Escherichia coli azoreductase, 
an enzyme expected to limit oral bioavailability through diazene 
cleavage in the intestine (Fig. S2).  
To determine the binding affinity of JB558 to the KATP 
channel subunit SUR1, as well as Epac2A, [3H]-glibenclamide 
displacement and FRET assays were performed. While trans-JB558 
bound SUR1 with ~10,000-fold less affinity than glimepiride (IC50 
(trans-JB558) = 37.3 µM; IC50 (Glim) = 1.8 nM) (Fig. 2a), it was 
able to strongly and light-dependently activate an Epac2A-camps 
biosensor containing the sulfonylurea binding domain12 (Fig. 2b-d). 
 
 
Fig. 2 (a) trans-JB558 and glimepiride (Glim) displace [3H]-glibenclamide 
from SUR1 (n = 3 repeats). (b) Glimepiride decreases FRET (shown here as 
an increase in R/Rmin) in HEK293T cells expressing full length Epac2-camps 
(n = 32 cells). (c) As for (b) but cis-JB558 ( = 561 nm) (n = 41 cells). (d) As 
for (c) but trans-JB558 (dark) (n = 37 cells). Values represent mean ± s.e.m. 
 
Electrophysiological recordings of K+ currents in 
HEK293T-SUR1-Kir6.2 cells revealed partial KATP channel 
blockade by trans-JB558, presumably due to the momentary 
stationary state favouring some continued cis-isomerisation (Fig. 
S3).  
We next assessed the photoswitching properties of JB558 
in native beta cells where sulfonylurea-mediated KATP channel-
Epac2A signalling is intimately linked to voltage-dependent Ca2+ 
channel (VDCC) activity and insulin exocytosis.13-16 As expected, 
JB558 was able to evoke large increases in intracellular Ca2+ 
concentrations in ~60% of beta cells following exposure to yellow 
( = 561 ± 5 nm)- (Fig. 3a and b), but not violet ( = 405 ± 5 nm)-
light (Fig. 3c). These effects were potentiated using a high 
concentration of glimepiride (Fig. 3d), and abrogated using 
diazoxide (Fig. 3e) to force open the KATP channel pore. Repeated 
switching of cytosolic Ca2+ concentrations could be achieved in the 
same islet following a brief period of dark exposure to induce trans-
JB558 accumulation (Fig. 3f).  
 
 
Fig. 3 (a) JB558 increases intracellular Ca2+ concentrations in 59% of beta 
cells residing within rodent islets of Langerhans following illumination with 
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 = 561 nm (scale bar = 75 µm) (n = 8 islets). (b) Photoswitching is rapid 
following exposure to  = 561 nm. (c) As for (b), but showing the absence of 
photoswitching with  = 405 nm. (d) A high concentration (100 µM) of 
glimepiride (Glim) augments JB558-stimulated Ca2+ rises. (e) Diazoxide (Dz) 
reverses cis-JB558-induced Ca2+ fluxes. (f) Reversible manipulation of Ca2+ 
transients can be achieved in the same islet following thermal back relaxation 
of JB558 in the dark (5 min between stimulation 1 and 2). Traces represent 
n = 6-10 recordings from 3 animals. Islets were maintained in 5 mM D-
glucose throughout. 
 
Similar to the results observed in rodent tissue, cis-JB588 
was able to confer light-sensitivity on Ca2+-spiking activity in human 
pancreatic islets (Fig. 4a-c), and this effect could be reversed 
following 5 min relaxation in the dark (Fig. 4d).  
 
 
 
Fig. 4 (a) JB558 increases intracellular Ca2+ concentrations in human beta 
cells in response to illumination with 561 nm to induce cis-formation (scale 
bar = 50 µm). (b) Photoswitching is rapid following exposure to 561 nm and 
can be potentiated with glimepiride (Glim). (c) cis-JB588 activates 54% of 
beta cells (n = 4 islets). (d) Reversible manipulation of Ca2+ rises following 
thermal back relaxation of JB558 in the dark (5 min between stimulation 1 
and 2). Traces represent n = 3-9 recordings from a single donor. Islets were 
maintained in 5 mM D-glucose throughout. 
 
To link photocontrol of Ca2+ levels with insulin secretion, 
batches of rodent islets were incubated with JB558 and exposed to 
either dark (no illumination) or light (λ = 560 ± 10 nm). JB558–
treated islets kept under dark conditions were no different to controls 
(5 mM glucose-alone) (Fig. 5a), suggesting that the observed 
stationary state KATP channel block was insufficient to elicit 
exocytosis. By contrast, irradiation dramatically stimulated insulin 
release (Fig. 5a). Finally, cytotoxicity assays demonstrated that 
JB558 did not adversely affect cell viability, as assessed using the 
vital stain calcein and the necrosis indicator propidium iodide (Fig. 
5b and c).  
 
 
Fig. 5 (a) JB558-treated islets respond to illumination with λ = 560 nm by 
increasing insulin secretion (**P<0.01 and NS, non-significant versus Con; 
one-way ANOVA). (b) Incubation with JB558 for 1 hr did not adversely 
alter cell viability versus dimethyl sulfoxide (DMSO), as assessed by the 
ratio of calcein (live):propidium iodide (dead) fluorescence (positive control; 
Triton X-100) (NS, non-significant versus Con; one-way ANOVA). (c) 
Representative images of islets stained with calcein and propidium iodide. In 
all cases, n = 36 islets per treatment group from 6 animals. Values represent 
mean ± s.e.m. 
 
The data presented here outline a synthetic route for the 
production of AzoSulfonylureas with red-shifted photochromism. 
Consistent with its sulfonylurea backbone, JB558 was able to bind 
SUR1 and activate Epac2A. Formation of cis-JB558 occurred with 
green-yellow light (λ = 520–561 nm), and thermal back relaxation in 
the dark yielded trans-JB558. While photoconversion between cis- 
and trans- forms was rapid in solution, it was slower in the tissue 
setting, taking minutes for reisomerisation. An effect of Fluo-2 
excitation on the isomer equilibrium cannot be excluded, although 
illumination at λ = 491 nm per se was unable to evoke Ca2+ rises in 
either Fluo-2- or Fura2 (λ = 340 nm/380 nm)-loaded islets (Fig. S4).  
A more plausible explanation is the inactivation of beta 
cell Epac2A-signalling, which may lag behind that of JB558 due to 
persistent mobilisation of intracellular Ca2+.1, 17 Such tissue effects 
may be desirable for the development of photopharmaceuticals, 
since pulsed illumination would reduce phototoxicity, while 
sustaining compound activity to match long-lasting (dozens of 
minutes) insulin peaks.4 Indeed, JB558 displayed almost 3-fold 
more potency than its blue-light activated predecessor JB253,6 most 
likely due to slower back-relaxation during the light pulses used in 
the secretion assays.  
Neither were we able to detect photoswitching of K+ 
currents in HEK293T cells overexpressing KATP channels, free from 
orthogonal wavelengths (Fig. S5). This was likely because 
HEK293T cells do not express sufficient Epac2A to allow JB558 to 
properly toggle KATP activity,
13, 15, 18 and/or the inability to deliver 
sufficient illumination using the non-coherent source on our patch-
clamp setup (520 nm (JB558) = 1.14 x 10
5 mol-1 cm-1; see SI).  
Nonetheless, we clearly show that JB558 light-
dependently binds Epac2A, allowing optical control of cell function 
and insulin secretion with λ = 560 nm in the most physiologically-
relevant testbed, viz the islets of Langerhans. Thus, JB558 represents 
a blueprint for red-shifted AzoSulfonylureas based upon heterocyclic 
azobenzenes. Further studies are now warranted to improve 
isomerisation kinetics in tissue to improve the use of JB558 as a 
research tool for rapid KATP channel manipulation. Importantly, 
similar synthetic approaches may also be applicable to other 
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clinically-relevant azobenzene-possessing compounds where steric 
hindrance may affect molecule motion e.g. neuromodulators,19 
neurotransmitters,20, 21 enzymes22 and antibiotics. 23 
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